Mesh.i
Checkpoint
Ncbi
Racine
Checkpoint
Ncbi
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Checkpoint (Ncbi)

Index « Mesh.i » - entrée « Cell Line »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Cell Hypoxia < Cell Line < Cell Line, Tumor  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 13.
Ident.Authors (with country if any)Title
000098 (2009) Misato Hashizume [Japon] ; Masahiko MiharaInfluence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling.
000151 (2010) Miho Suzuki [Japon] ; Misato Hashizume ; Hiroto Yoshida ; Masahiko MiharaAnti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule.
000164 (2009) Yukio Mano [Japon] ; Kiyosumi Shibata ; Seiji Sumigama ; Hiromi Hayakawa ; Kazuhiko Ino ; Eiko Yamamoto ; Hiroaki Kajiyama ; Akihiro Nawa ; Fumitaka KikkawaTocilizumab inhibits interleukin-6-mediated matrix metalloproteinase-2 and -9 secretions from human amnion cells in preterm premature rupture of membranes.
000192 (2009) Sandrine Crabé [Canada] ; Angélique Guay-Giroux ; Aurélie Jeanne Tormo ; Dorothée Duluc ; Rami Lissilaa ; Florence Guilhot ; Ulrick Mavoungou-Bigouagou ; Fouad Lefouili ; Isabelle Cognet ; Walter Ferlin ; Greg Elson ; Pascale Jeannin ; Jean-François GauchatThe IL-27 p28 subunit binds cytokine-like factor 1 to form a cytokine regulating NK and T cell activities requiring IL-6R for signaling.
000231 (2010) Jordan S. Fridman [États-Unis] ; Peggy A. Scherle ; Robert Collins ; Timothy C. Burn ; Yanlong Li ; Jun Li ; Maryanne B. Covington ; Beth Thomas ; Paul Collier ; Margaret F. Favata ; Xiaoming Wen ; Jack Shi ; Ryan Mcgee ; Patrick J. Haley ; Stacey Shepard ; James D. Rodgers ; Swamy Yeleswaram ; Greg Hollis ; Robert C. Newton ; Brian Metcalf ; Steven M. Friedman ; Kris VaddiSelective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.
000262 (2010) Soken-Nakazawa J. Song [Japon] ; Naohisa Tomosugi ; Hiroshi Kawabata ; Takayuki Ishikawa ; Teppei Nishikawa ; Kazuyuki YoshizakiDown-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease.
000476 (2011) Christoph Garbers [Allemagne] ; Wolfgang Thaiss ; Gareth W. Jones ; Georg H. Waetzig ; Inken Lorenzen ; Florence Guilhot ; Rami Lissilaa ; Walter G. Ferlin ; Joachim Grötzinger ; Simon A. Jones ; Stefan Rose-John ; Jürgen SchellerInhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor.
000A31 (2014) Yuji Yoshida [Japon] ; Toshio Tanaka [Japon]Interleukin 6 and rheumatoid arthritis.
000E32 (2015) Lin Yang [République populaire de Chine] ; Rui Xing [République populaire de Chine] ; Changhong Li [République populaire de Chine] ; Yuan Liu [République populaire de Chine] ; Lin Sun [République populaire de Chine] ; Xiangyuan Liu [République populaire de Chine] ; Yongfu Wang [République populaire de Chine]Active immunization with Tocilizumab mimotopes induces specific immune responses.
001496 (2017) Amélie Moreau [France] ; Marc Le Vée [France] ; Elodie Jouan [France] ; Claire Denizot [France] ; Yannick Parmentier [France] ; Olivier Fardel [France]Effect of Gevokizumab on Interleukin-1β-Mediated Cytochrome P450 3A4 and Drug Transporter Repression in Cultured Human Hepatocytes.
001944 (2016) Fen Sheng ; Minghui Han ; Zongxuan Huang ; Lingling ZhangInterleukin 6 receptor inhibitor tocilizumab suppresses cytokine expression, inflammasome activation and phagocytosis in a cell model of sepsis.
001B99 (2018) Chuanfei Yu [République populaire de Chine] ; Junxia Cao [République populaire de Chine] ; Lan Wang [République populaire de Chine] ; Yalan Yang [République populaire de Chine] ; Yongbo Ni [République populaire de Chine] ; Junzhi Wang [République populaire de Chine]Measuring the bioactivity of anti-IL-6/anti-IL-6R therapeutic antibodies: presentation of a robust reporter gene assay.
001D33 (2019) Niklas Prenissl [Allemagne] ; Juliane Lokau [Allemagne] ; Stefan Rose-John [Allemagne] ; Johannes Haybaeck [Autriche] ; Christoph Garbers [Allemagne]Therapeutic blockade of the interleukin-6 receptor (IL-6R) allows sIL-6R generation by proteolytic cleavage.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Ncbi/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Mesh.i -k "Cell Line" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Mesh.i  \
                -Sk "Cell Line" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Cell Line
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021